New Developments in Allergic Asthma Treatment

Allergic asthma is the most common form of asthma and can occur when a patient’s airways are extra sensitive to certain allergens. Symptoms include coughing/wheezing, shortness of breath, quick breathing or chest tightness. Allergic asthma is most commonly treated with  antihistamines, inhaled steroids, and bronchodilators. Longer-lasting treatments are also available.

This education center aims to arm physicians with the latest, most important, and most practice-changing research in prevention, treatment, and management of allergic asthma.

 
FDA Grants Tezepelumab Priority Review as Asthma Treatment

FDA Grants Tezepelumab Priority Review as Asthma Treatment

The FDA has granted Priority Review for tezepelumab and accepted a Biologics License Application (BLA) for patients with asthma...
Study Shows FeNO Can Help Predict Asthma Risk

Study Shows FeNO Can Help Predict Asthma Risk

While fractional exhaled nitric oxide (FeNO) has been shown to have potential as a prognostic biomarker in asthma, a recent study attempted to provide more concrete proof of the benefits of its potential use...
STUDY: Asthma Improves for Most Patients Switched to Mepolizumab

STUDY: Asthma Improves for Most Patients Switched to Mepolizumab

For patients with uncontrolled, severe eosinophilic asthma, “almost all” who switched to mepolizumab after receiving omalizumab had an improvement in at least one clinical outcome...
NAVIGATOR: Tezepelumab Improves Lung Function, Asthma Scores

NAVIGATOR: Tezepelumab Improves Lung Function, Asthma Scores

Results from a large phase 3 trial of tezepelumab showed the monoclonal antibody performed better than placebo at improving lung function and asthma scores in patients with severe asthma...
FDA to Review BLA for Tezepelumab for Severe Asthma Treatment

FDA to Review BLA for Tezepelumab for Severe Asthma Treatment

The manufacturer of tezepelumab, an investigational treatment for severe asthma, has submitted a Biologics License Application to the FDA...

Loading...

© 2021 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information